Takeda Pharmaceutical Company Limited Price & Performance (TAK)
Stock Performance
TAK:NYSE
$15.18USD1.13% · $0.17
After Hours
+0.13% · $0.02
- $15.01
- $15.24
- $15.01
- $48.13B
- 34.5
- 1.29M
- $15.24
- $12.58
- 4.25%
Open
High
Low
Market Cap
P/E Ratio
Volume
Year High
Year Low
Dividend Yield
What's Happening
Peers
Income Statement
Revenue
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Revenue | ¥3.3T | ¥3.2T | ¥3.6T | ¥4T | ¥4.3T |
Cost of Revenue | ¥1.1T | ¥994B | ¥1.1T | ¥1.2T | ¥1.4T |
Gross Profit | ¥2.2T | ¥2.2T | ¥2.5T | ¥2.8T | ¥2.8T |
Gross Profit % | 67% | 69% | 69% | 69% | 66% |
R&D Expenses | ¥492B | ¥456B | ¥526B | ¥633B | ¥730B |
Cash Flow
Net Income
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Net Income | ¥44B | ¥376B | ¥230B | ¥317B | ¥144B |
Dep. & Amort. | ¥584B | ¥560B | ¥583B | ¥664B | ¥728B |
Def. Tax | -¥105B | -¥9.9B | ¥72B | ¥58B | -¥91B |
Stock Comp. | ¥29B | ¥38B | ¥43B | ¥61B | ¥71B |
Chg. in WC | ¥95B | ¥276B | ¥99B | -¥25B | -¥256B |
Balance Sheet
Cash
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Cash | ¥638B | ¥966B | ¥850B | ¥534B | ¥458B |
ST Investments | ¥16B | ¥37B | ¥25B | ¥20B | ¥15B |
Cash & ST Inv. | ¥653B | ¥1T | ¥875B | ¥554B | ¥458B |
Receivables | ¥785B | ¥813B | ¥724B | ¥682B | ¥698B |
Inventory | ¥760B | ¥754B | ¥853B | ¥986B | ¥1.2T |
Related
Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.